# Polomar Health Services, Inc. (PMHS) · Edgar & Edgarette company card

> Polomar Health Services (PMHS) grew revenue 1002% in FY2025 to $1 million, operating margin -1628% against a -3.8% median for pharmaceutical preparations, equity -313% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1265521 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/PMHS) · [JSON](https://www.pops4.com/boards/company/PMHS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $648,231 |
| Revenue growth, 1 year | 1002.0% |
| Revenue growth per year | 165.7% |
| Operating margin | -1627.5% (prior year -2209.1%) |
| Net margin | -1650.8% |
| Operating cash flow | −$395,995 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $132,150 |
| Long-term debt | — |
| Total assets | $390,043 |
| Total equity | −$1M |
| Equity ÷ assets | -313.4% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -318.03 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, earlier statements no longer to be relied on, late quarterly report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$396K in FY2025); operating loss: a margin of -1627.5% in FY2025; revenue is hard to predict: its 80% range is ±48%

## Edgarette's reading

Exposure: revenue $648K (FY2025). Experience: revenue up 1002.0% on the year, up 165.7% a year over 3 years; operating margin -1627.5%, up from -2209.1%. Soundness: equity -313.4% of assets (liabilities exceed assets). Credibility: four or more audited years, moderate weight, marked down from reasonable: on 2026-11-03 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Range: 80% of past cases like this landed between $2.6M and $7.3M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.4M to $7.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1627.5% against a -3.8% median; growth 1002.0% against 13.7%.

Range logged 2026-10-20, receipt 6e8e467d8eeeefcb, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226014496/0001493152-26-014496-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226049808/0001493152-26-049808-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-18 ([filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226024128/0001493152-26-024128-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-07-17 ([filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226033740/0001493152-26-033740-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-19 ([filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226047580/0001493152-26-047580-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226052285/0001493152-26-052285-index.htm)
- 8-K · filed 2026-11-13 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226051849/0001493152-26-051849-index.htm)
- 8-K · filed 2026-11-03 · 4.02 Non-Reliance on Previously Issued Financial Statements; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226049808/0001493152-26-049808-index.htm)
- 8-K · filed 2026-10-19 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226047580/0001493152-26-047580-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226038324/0001493152-26-038324-index.htm)
- 8-K · filed 2026-07-20 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1265521/000149315226033906/0001493152-26-033906-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001265521.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1265521

## Cite

POPS4, Edgar & Edgarette: Polomar Health Services, Inc. (PMHS) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/PMHS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

